Please login to the form below

Not currently logged in
Email:
Password:

respiratory syncytial virus

This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

Following after, Ablynx is expecting phase IIb clinical trial results for its respiratory syncytial virus (RSV) therapy ALX-0171 before the end of the year.

Latest news

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    This is the second pipeline disappointment for Regeneron in recent months after it abandoned respiratory syncytial virus (RSV) candidate suptavumab, which failed to hit the mark in a phase III trial

  • Janssen’s quest to prevent diseases taking hold Janssen’s quest to prevent diseases taking hold

    Janssen’s acquisition of Crucell in 2011 brought it a suite of promising platforms covering HIV, a universal flu vaccine, respiratory syncytial virus (RSV), which is an infection of the lungs ... and respiratory tract that affects children and the

  • Regeneron drops RSV drug Regeneron drops RSV drug

    Regeneron has said it will end the development of its late-stage candidate for the prevention of respiratory syncytial virus (RSV) infections after disappointing results in a phase III trial. ... At the moment the only approved prophylaxis against the

  • J&J aiming for above-average growth thanks to stream of blockbusters J&J aiming for above-average growth thanks to stream of blockbusters

    The remaining two would-be blockbusters are both antiviral drugs. Lumicitabine for respiratory syncytial virus (RSV) infection was acquired by the company along with Alios BioPharma in 2014 for $1.75bn

  • Sanofi buys into AZ drug for preventing RSV infections Sanofi buys into AZ drug for preventing RSV infections

    Sanofi is paying 120m upfront for a share in a respiratory syncytial virus (RSV) drug in development at AstraZeneca's MedImmune unit. ... RSV is the most common cause of acute lower respiratory tract infection in children, with around 2.5m cases each

More from news
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.

  • Pharma deals during June 2013 Pharma deals during June 2013

    Still in the respiratory space, Teva acquired the privately owned drug delivery company MicroDose Therapeutx for an initial $40m with further payments of up to $125m. ... The deal brings to Teva a multi dose dry powder nebuliser technology and MDT-637, a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics